Morgan Adam's Insider Trades & SAST Disclosures
Morgan Adam's most recent trade in Heron Therapeutics Inc was a trade of 35,900 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Jan. 31, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Morgan Adam.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Heron Therapeutics Inc | Adam Morgan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 35,900 | 35,900 | - | - | Stock Option (Right to Buy) | |
| Heron Therapeutics Inc | Adam Morgan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 17,950 | 69,777 (0%) | 0% | 0 | Common Stock | |
| Heron Therapeutics Inc | Adam Morgan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jan 2025 | 35,900 | 35,900 | - | - | Stock Option (Right to Buy) | |
| Heron Therapeutics Inc | Adam Morgan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jan 2025 | 17,950 | 69,777 (0%) | 0% | 0 | Common Stock | |
| Alimera Sciences Inc. | Adam Morgan | Director, Ten Percent Owner | Sale or transfer of securities back to the company at price $ 0.00 per share. | 16 Sep 2024 | 9,429,808 | 0 (0%) | 189% | - | Common Stock | |
| Alimera Sciences Inc. | Adam Morgan | Director, Ten Percent Owner | Sale or transfer of securities back to the company at price $ 0.00 per share. | 16 Sep 2024 | 4,178,725 | 0 (0%) | 84% | - | Common Stock | |
| Alimera Sciences Inc. | Adam Morgan | Director, Ten Percent Owner | Sale or transfer of securities back to the company at price $ 0.00 per share. | 16 Sep 2024 | 800,000 | 0 | - | - | Warrants | |
| Alimera Sciences Inc. | Adam Morgan | Director, Ten Percent Owner | Sale or transfer of securities back to the company at price $ 0.00 per share. | 16 Sep 2024 | 50,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Alimera Sciences Inc. | Adam Morgan | Director, Ten Percent Owner | Sale or transfer of securities back to the company at price $ 0.00 per share. | 16 Sep 2024 | 1,825 | 0 | - | - | Stock Option (Right to Buy) | |
| Heron Therapeutics Inc | Morgan Adam | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2024 | 83,685 | 83,685 | - | - | Stock Option (Right to Buy) | |
| Heron Therapeutics Inc | Adam Morgan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2024 | 13,948 | 51,827 (0%) | 0% | 0 | Common Stock | |
| Alimera Sciences Inc. | Adam Morgan | Director, Ten Percent Owner | 15 Aug 2023 | 4,845,392 | 6,505,046 (130%) | 97% | 1.7 | 8,237,166 | Common Stock | |
| Alimera Sciences Inc. | Adam Morgan | Director, Ten Percent Owner | 15 Aug 2023 | 4,178,725 | 4,178,725 (84%) | 84% | 1.7 | 7,103,833 | Common Stock | |
| Alimera Sciences Inc. | Adam Morgan | Director, Ten Percent Owner | 15 Aug 2023 | 2,924,762 | 9,429,808 (189%) | 58% | 2.1 | 6,142,000 | Common Stock | |
| Alimera Sciences Inc. | Adam Morgan | Director, Ten Percent Owner | 15 Aug 2023 | 8,117 | 0 | - | - | Series B Convertible Preferred Stock | ||
| Alimera Sciences Inc. | Adam Morgan | Director, Ten Percent Owner | 15 Aug 2023 | 7,000 | 0 | - | - | Series B Convertible Preferred Stock | ||
| Alimera Sciences Inc. | Adam Morgan | Director, Ten Percent Owner | 15 Aug 2023 | 6,000 | 0 | - | - | Series B Convertible Preferred Stock | ||
| Heron Therapeutics Inc | Adam Morgan | Director | Purchase of securities on an exchange or from another person at price $ 1.37 per share. | 21 Jul 2023 | 2,486,744 | 6,986,744 (7%) | 2% | 1.4 | 3,406,839 | Common Stock, par value $0.01 per share |
| Heron Therapeutics Inc | Adam Morgan | Director | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 21 Jul 2023 | 1,162,891 | 1,162,891 | - | - | Pre-funded Warrants to Purchase Common Stock | |
| Alimera Sciences Inc. | Adam Morgan | Director, Ten Percent Owner | Other type of transaction at price $ 0.00 per share. | 17 May 2023 | 2,057,143 | 800,000 | - | - | Warrants | |
| Alimera Sciences Inc. | Adam Morgan | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 1.70 per share. | 17 May 2023 | 1,401,901 | 1,659,654 (33%) | 28% | 1.7 | 2,383,232 | Common Stock |
| Alimera Sciences Inc. | Adam Morgan | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 17 May 2023 | 8,117 | 8,117 | - | - | Series B Convertible Preferred Stock | |
| Alimera Sciences Inc. | Adam Morgan | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 17 May 2023 | 7,000 | 7,000 | - | - | Series B Convertible Preferred Stock | |
| Alimera Sciences Inc. | Adam Morgan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Mar 2023 | 1,825 | 1,825 | - | - | Stock Option (Right to Buy) | |
| Heron Therapeutics Inc | Adam Morgan | Director, See Notes 2 & 3 | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2023 | 227,272 | 227,272 | - | - | Stock Option (Right to Buy) | |
| Heron Therapeutics Inc | Adam Morgan | Director, See Notes 2 & 3 | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2023 | 37,879 | 37,879 (0%) | 0% | 0 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges